Related Experiment Video
Updated: Jan 3, 2026
Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
Published on: February 8, 2017
Advanced nanoscale carrier-based approaches to overcome biopharmaceutical issues associated with anticancer drug
Hira Choudhury1, Rahul Maheshwari2, Manisha Pandey1
1The International Medical University, School of Pharmacy, Department of Pharmaceutical Technology, 57000, Kuala Lumpur, Malaysia.
Abstract:
Etoposide (ETS), topoisomerase-II inhibitor, is a first-line anticancer therapeutics used in diverse cancer types. However, the therapeutic potential of this molecule has mainly impeded due to its detrimental toxicity profile, unfavorable rejection by the cancer cells due to P-glycoprotein (P-gp) efflux activity, and rapid hepatic clearance through extensive metabolism by Cytochrome-P450. To increase the therapeutic potency without significant adverse effects, the implication of novel ETS-nanoformulation strategies have recommended mainly. Nanomedicine based nanoformulation approaches based on nanoparticles (NPs), dendrimers, carbon-nanotubes (CNTs), liposomes, polymeric micelles, emulsions, dendrimers, solid-lipid NPs, etc offers immense potential opportunities to improve the therapeutic potential of pharmaceutically problematic drugs. This review provides an up-to-date argument on the work done in the field of nanomedicine to resolve pharmacokinetic and pharmacodynamic issues associated with ETS. The review also expounds the progress in regards to the regulatory, patenting and clinical trials related to the innovative formulation aspects of ETS.
Insights
Novel nanomedicine strategies enhance etoposide (ETS) cancer therapy by overcoming drug resistance and toxicity. These nanoformulations improve drug delivery and efficacy for better patient outcomes.
Area of Science:
- Oncology
- Nanomedicine
- Pharmacology
Background:
- Etoposide (ETS) is a key topoisomerase-II inhibitor for cancer treatment.
- ETS efficacy is limited by toxicity, P-glycoprotein efflux, and rapid Cytochrome-P450 metabolism.
- Novel nanoformulation strategies are crucial for improving ETS therapeutic potential.
Purpose of the Study:
- To review nanomedicine approaches for addressing ETS pharmacokinetic and pharmacodynamic challenges.
- To highlight advancements in regulatory, patenting, and clinical trials for ETS nanoformulations.
Main Methods:
- Review of existing literature on nanomedicine applications for etoposide.
- Analysis of various nanoformulation types including nanoparticles, liposomes, and micelles.
- Examination of regulatory and clinical trial data for innovative ETS formulations.
Main Results:
- Nanomedicine offers diverse platforms (NPs, liposomes, micelles) to enhance ETS delivery and efficacy.
- Nanoformulations can mitigate ETS toxicity and overcome cancer cell drug resistance.
- Progress in regulatory approval and clinical trials indicates the viability of novel ETS formulations.
Conclusions:
- Nanomedicine-based strategies show significant promise in overcoming ETS limitations.
- Innovative ETS nanoformulations can improve therapeutic outcomes and reduce adverse effects.
- Further research and clinical translation of these nanomedicines are warranted.
